☆ 4.7 Article

Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy

JAMA NETWORK OPEN (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Oncology

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Beverly Moy et al.

Summary: ASCO Rapid Recommendations Updates are revisions to specific ASCO guideline recommendations based on new and practice-changing data. These updates are supported by evidence review and follow ASCO's guideline development processes. The articles aim to disseminate updated recommendations in a timely manner to inform healthcare practitioners and the public about the best available cancer care options.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database

Daniel S. S. Peiffer et al.

Summary: A retrospective cohort study of 1,136,016 patients with ERBB2-negative and ERBB2-low breast cancer found minimal prognostic differences between the two subtypes, indicating that ERBB2-low breast cancer should not be classified as a distinct disease entity.

JAMA ONCOLOGY (2023)

Add to Collection

Article Oncology

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue

Aileen Fernandez et al.

Summary: The current standard ERBB2 IHC assay may not be suitable for selecting patients with low ERBB2 positivity for treatment with T-DXd, as the accuracy of scoring for ERBB2 INC in the low range (0 and 1+) was poor in this study, raising the risk of misassigning patients for treatment with T-DXd.

JAMA ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)

Veronique Dieras et al.

CANCER RESEARCH (2022)

Add to Collection

Meeting Abstract Oncology

Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancer

Rodrigo Sanchez-Bayona et al.

CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update

Beverly Moy et al.

Summary: ASCO Rapid Recommendations Updates aim to disseminate timely updated cancer care options to healthcare practitioners and the public.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi et al.

Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer

Paolo Tarantino et al.

Summary: This study investigated whether low ERBB2 expression is associated with distinct clinicopathologic characteristics and prognosis among patients with hormone receptor-positive and triple-negative breast cancer. The results did not support the interpretation of ERBB2-low breast cancer as a distinct biologic subtype. ERBB2-low expression was positively associated with the level of ER expression, suggesting confounding effects in prognostic analyses of ERBB2-low expression.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Hope S. Rugo et al.

Summary: The study demonstrates the potential of Sacituzumab govitecan in the treatment of breast cancer, with a longer progression-free survival compared to traditional chemotherapy regimens and a manageable safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study

Yingbo Shao et al.

Summary: The study found that HER2-low expression does not affect the clinical efficacy of palbociclib for patients with HR+/HER2- metastatic breast cancer. The current study does not support incorporating HER2-low into systemic therapy decisions for patients treated with CDK4/6 inhibitors.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France

Ombline de Calbiac et al.

Summary: In a study of breast cancer patients, it was found that patients with ERBB2-low expression had slightly better overall survival compared to those with completely ERBB2-zero tumors, but identical progression-free survival under first-line treatments, which could help with treatment selection.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Oncology

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Francesco Schettini et al.

Summary: Novel antibody-drug conjugates targeting HER2 have shown high activity in HER2-negative breast cancer with low HER2 expression, but the clinical and molecular characteristics of HER2-low breast cancer remain unclear. This study reveals that HER2-low is more common in HR-positive disease than in TNBC, and emphasizes the significant biological heterogeneity of HER2-low BC, highlighting the importance of reproducible and sensitive assays for measuring low HER2 expression.

NPJ BREAST CANCER (2021)

Add to Collection

Letter Medicine, General & Internal

The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer

Kelvin K. H. Bao et al.

JAMA NETWORK OPEN (2021)

Add to Collection

Review Oncology

Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer

Jason A. Mouabbi et al.

Summary: This review discusses the biological features of HR + / HER2- mBC, the different mechanisms of resistance to endocrine therapy, and the management of mBC as the disease transitions from endocrine-sensitive to endocrine-resistant. The evolving treatment landscape of HR + / HER2- mBC presents both an art and a challenge for clinicians.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Review Oncology

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Paolo Tarantino et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.